Takeda Pharmaceutical : Filing of Corporate Governance Report to the Tokyo Stock Exchange

About this update from Takeda Pharmaceutical Co. Ltd.

OSAKA, Japan, and CAMBRIDGE, Massachusetts, July 9, 2026 - Takeda (TSE:4502/NYSE:TAK) today filed its Corporate Governance Report with the Tokyo Stock Exchange ("TSE") in accordance with the regulations* for TSE listed companies. The Report can be accessed on Takeda's website at: https://www.takeda.com/about/corporate-governance/charters-and-reports/ The Report is prepared in line with the current Corporate Governance Code. It describes Takeda's latest corporate governance features, including the new composition of the Board of Directors following the 150th Annual General Meeting of Shareholders held on June 24, 2026. Key elements of Takeda's Corporate Governance Report: Takeda ensures the transparency and objectivity of the Board of Directors' discussions by maintaining a high ratio of independent external directors (three internal directors and eight independent external directors) and having an independent external director serve as Chair of the Board Meeting. The Board of Directors is composed of diverse members with various background, experiences and knowledge (BOD Skill Matrix), to enable strategic discussions and effective supervision of the Company. The Audit and Supervisory Committee and the Nomination/Compensation Committees, the latter being voluntary advisory committees of the Board of Directors, are composed entirely of independent external directors, including each head/chairperson, in order to ensure the independence of each committee. Takeda has internal management committees composed of Internal Directors, to whom authority is delegated by the BOD, and the Takeda Executive Team, which consists of the function heads of the Takeda Group. Matters determined by such committees are then reported to the BOD and the BOD supervises them in an appropriate manner. Takeda has consolidated and clarified key Board-related standards in its Corporate Governance Policy, including matters relating to independence, director qualifications and eligibility, conflicts of interest, service on other boards and Board service. The policy is disclosed in the Corporate Governance section of Takeda's website. Takeda's latest Corporate Governance Report can be found on the information disclosure site operated by the Japan Exchange Group which consists of the TSE and other exchanges in Japan at: https://www2.jpx.co.jp/tseHpFront/CGK020010Action.do?Show=ShowGo to http...

View stock analysis, news, and events for Takeda Pharmaceutical Co. Ltd.